Neuroscience Today—June 3, 2026

This week’s Neuroscience update highlights regulatory progress, clinical data readouts, digital-health innovation, scientific advances, and evolving market-access developments across neurological disorders.

In Today’s Newsletter

Dive deeper

💉 Vyepti cleared in South Korea for migraine prevention [1] [South Korea • 26 May 2026]

https://news.cision.com/h–lundbeck-a-s/r/lundbeck-receives-marketing-authorization-for-vyepti—eptinezumab–in-south-korea-for-the-preventiv,c4352361
Context: Lundbeck’s Vyepti (eptinezumab) is an IV anti-CGRP monoclonal antibody for adult migraine prevention.
Key point: South Korea’s MFDS granted marketing authorization, supported by Phase 3 studies including SUNRISE in a predominantly Asian chronic-migraine population.
Implication: May influence prescriber choice and payer reviews pending full data.

📱 Theranica adds AI features and coverage for Nerivio [2] [US • 28 May 2026]

https://www.prnewswire.com/news-releases/theranica-advances-nerivio-as-a-transformative-therapy-for-personalized-migraine-care-302783660.html
Context: Nerivio is Theranica’s remote electrical neuromodulation wearable for acute and preventive migraine care.
Key point: Theranica announced AI-based “Your Day Ahead” features, real-world safety data, and US coverage reaching more than 150 million covered lives.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🟣 Axsome backs migraine-awareness campaign [3] [US • 01 Jun 2026]

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-partners-headache-alliance-highlight-impact
Context: Axsome Therapeutics is supporting Headache Alliance education during Migraine and Headache Awareness Month.
Key point: Activities include the first Headache in the City campaign in New York City and a purple lighting of One World Trade Center.
Implication: May expand screening, initiation, and follow-up at scale.

🧠 AHS sets 2026 headache-science agenda [4] [US • 27 May 2026]

https://www.businesswire.com/news/home/20260527631335/en/Groundbreaking-Headache-Medicine-Research-on-New-Frontiers-in-Treatment-Biomarkers-and-the-Gut-Brain-Axis-to-be-Presented-at-the-American-Headache-Society-68th-Annual-Scientific-Meeting
Context: The American Headache Society 68th Annual Scientific Meeting runs 04–07 Jun 2026 in Orlando, Florida.
Key point: The program includes more than 350 abstracts across treatment, biomarkers, gut-brain research, digital biomarkers, and personalized medicine.
Implication: May influence prescriber choice and payer reviews pending full data.

⚕️ Otsuka reports centanafadine ADHD post hoc analyses [5] [US • 29 May 2026]

https://www.otsuka.co.jp/en/company/newsreleases/2026/20260529_1.html
Context: Centanafadine is Otsuka’s investigational NDSRI under US FDA Priority Review for ADHD, with a PDUFA date of 24 Jul 2026.
Key point: Post hoc Phase 3 analyses in 744 adults associated centanafadine with improved executive function and emotional dysregulation at Week 6.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Praxis pauses POWER2 after vormatrigine miss [6] [US • 01 Jun 2026]

https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-vormatrigine-program-update
Context: POWER1 is a Phase 2/3 study of vormatrigine in highly refractory focal-onset seizures.
Key point: Vormatrigine did not meet the primary success measure, though Praxis reported a met 50% response-rate measure and a stronger high-dose signal later in the study.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 NeuExcell presents NXL-004 glioma data at ASCO [7] [US • 31 May 2026]

https://www.manilatimes.net/2026/05/31/tmt-newswire/globenewswire/neuexcell-therapeutics-announces-encouraging-data-of-nxl-004-in-recurrent-malignant-glioma-at-2026-asco/2355169
Context: NXL-004 is NeuExcell’s first-in-class AAV6-NeuroD1 in vivo cell-conversion therapy for recurrent malignant glioma.
Key point: First-in-human data in 11 patients reported no drug-related serious adverse events and encouraging survival signals versus historical benchmarks.
Implication: May influence prescriber choice and payer reviews pending full data.

🧩 Ozanimod cognition analysis in relapsing MS [8] [US • 27 May 2026]

https://www.neurologylive.com/view/ozanimod-preserves-multiple-sclerosis-cognition-new-3-year-analysis
Context: ENLIGHTEN is an open-label Phase 3b study of ozanimod (Zeposia, BMS) in adults with relapsing MS.
Key point: An ad hoc analysis reported largely preserved SDMT-defined cognition over three years, with wide confidence intervals limiting interpretation.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🗣️ National MS Society releases patient-voice report [9] [US • 27 May 2026]

https://www.prnewswire.com/news-releases/national-ms-society-releases-voice-of-the-patient-report-capturing-the-lived-reality-of-multiple-sclerosis-302782506.html
Context: The Voice of the Patient report draws on nearly 3,000 survey responses and direct testimony from people affected by MS.
Key point: Respondents prioritized better treatments for fatigue, walking, spasticity, cognition, and bladder control, plus earlier diagnosis and progression control.
Implication: May expand screening, initiation, and follow-up at scale.

⚖️ Biogen faces Italian antitrust probe over MS test access [10] [Italy • 27 May 2026]

https://www.fiercepharma.com/marketing/biogen-investigated-italian-regulator-over-multiple-sclerosis-market-abuse-claims
Context: Italy’s AGCM is investigating Biogen and its Italian subsidiary over alleged conduct involving Stratify anti-JCV testing for natalizumab.
Key point: The regulator alleges Biogen may have limited access for patients using Sandoz’s Tyruko biosimilar; Biogen’s premises were inspected on 26 May 2026.
Implication: Introduces competition that may affect pricing and formulary access.

Why it Matters